Access criteria for anti-TNF agents in spondyloarthritis: influence on comparative 1-year cost-effectiveness estimates

Stephanie Harvard (1) , Daphne Guh (2) , Nick Bansback (1) , Pascal Richette (3) , Alain Saraux (4, 5) , Bruno Fautrel (6) , Aslam Anis (7)

1 UPMC - Université Pierre et Marie Curie - Paris 6
2 Centre for Health Evaluation and Outcome Sciences
3 Centre Viggo-Petersen, service de rhumatologie
4 LBAI - Lymphocytes B, Autoimmunité et Immunothérapies
5 CIC Brest
6 UPMC - Université Pierre et Marie Curie - Paris 6 - UFR de Médecine Pierre et Marie Curie
7 UBC - University of British Columbia

Domaines: Sciences du Vivant [q-bio]; Médecine humaine et pathologie; Rhumatologie et système ostéo-articulaire

Stephanie Harvard, Daphne Guh, Nick Bansback, Pascal Richette, Alain Saraux, et al.. Access criteria for anti-TNF agents in spondyloarthritis: influence on comparative 1-year cost-effectiveness estimates. Cost Effectiveness and Resource Allocation, 2017, 15 (1). ⟨hal-02048666⟩